Determining the impact of cannabis use and severity on tobacco cessation outcomes: study protocol for a prospective tobacco treatment trial

被引:1
作者
Walters, Kyle J. J. [1 ]
Baker, Nathaniel L. L. [2 ]
Tomko, Rachel L. L. [1 ]
Gray, Kevin M. M. [1 ]
Carpenter, Matthew J. J. [1 ,3 ]
McClure, Erin A. A. [1 ,3 ]
机构
[1] Med Univ South Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861, Charleston, SC 29425 USA
[2] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA
[3] Med Univ South Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St, Charleston, SC 29425 USA
关键词
Tobacco cessation; Treatment; Cannabis; Marijuana; Varenicline; Co-use; Polysubstance use; Pharmacotherapy; SUSTAINED-RELEASE BUPROPION; RECEPTOR PARTIAL AGONIST; SUBSTANCE USE DISORDERS; UNITED-STATES; SMOKING-CESSATION; CIGARETTE-SMOKING; PROPENSITY SCORE; CO-USE; N-ACETYLCYSTEINE; NATIONAL-SURVEY;
D O I
10.1186/s40359-023-01060-2
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
BackgroundSeveral evidence-based tobacco cessation treatment strategies exist, though significant barriers to cessation remain which must be addressed to improve abstinence rates for sub-populations of those smoking cigarettes. Cannabis co-use among those who use tobacco is common and appears to be increasing among adults in the United States (US). The literature evaluating the impact of cannabis use on tobacco cessation has been mixed and has several important limitations, which precludes development of treatment recommendations specific to individuals who use tobacco and co-use cannabis. To date, no prospective studies have evaluated the impact of cannabis use and severity on tobacco cessation or quantified cannabis use changes during tobacco treatment to assess for concurrent reductions, abstinence, or compensatory (i.e., increased) cannabis use. This study's aims are to: (1) evaluate tobacco cessation outcomes among participants who co-use cannabis compared to participants only using tobacco, (2) using daily diaries and biochemical verification, assess changes in cannabis use during tobacco treatment, and (3) assess for a dose-dependent impact of cannabis use on tobacco cessation.MethodA multi-site, prospective, quasi-experimental 12-week tobacco treatment trial enrolling treatment-seeking adults (ages 18-40; N = 208) from three sites across South Carolina (US) who use tobacco daily and oversampling (2:1) those who co-use cannabis. Participants receive tobacco cessation pharmacotherapy (varenicline) paired with behavioral support, while cannabis use is not addressed as part of treatment. The primary outcome is 7-day point prevalence tobacco abstinence at the week 12 end of treatment visit, measured via biochemical verification and self-report. Secondary outcome measures include changes in cannabis use (via biochemical verification and self-report) during tobacco cessation treatment.DiscussionResults from this trial have the potential to inform tobacco treatment among those co-using cannabis, which may require a tailored approach to address the role of cannabis in quitting tobacco.
引用
收藏
页数:9
相关论文
共 62 条
  • [1] Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial
    Anthenelli, Robert M.
    Benowitz, Neal L.
    West, Robert
    St Aubin, Lisa
    McRae, Thomas
    Lawrence, David
    Ascher, John
    Russ, Cristina
    Krishen, Alok
    Evins, A. Eden
    [J]. LANCET, 2016, 387 (10037) : 2507 - 2520
  • [2] Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
    Austin, Peter C.
    Stuart, Elizabeth A.
    [J]. STATISTICS IN MEDICINE, 2015, 34 (28) : 3661 - 3679
  • [3] Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers A Randomized Clinical Trial
    Benowitz, Neal L.
    Pipe, Andrew
    West, Robert
    Hays, J. Taylor
    Tonstad, Serena
    Mcrae, Thomas
    Lawrence, David
    St Aubin, Lisa
    Anthenelli, Robert M.
    [J]. JAMA INTERNAL MEDICINE, 2018, 178 (05) : 622 - 631
  • [4] Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006103.pub6, 10.1002/14651858.CD009329.pub2]
  • [5] Center for Behavioral Health Statistics and Quality, 2016, 2015 National Survey on Drug Use and Health
  • [6] Center for Behavioral Health Statistics and Quality, 2015, 2014 National Survey on Drug Use and Health: Methodological summary and definitions
  • [7] Age groups differences in the prevalence and popularity of individual tobacco product use in young adult and adult marijuana and tobacco co-users and tobacco-only users: Findings from Wave 4 of the population assessment of tobacco and health study
    Cohn, Amy M.
    Chen, Sixia
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2022, 233
  • [8] Cornelius ME, 2022, MMWR-MORBID MORTAL W, V71, P397, DOI 10.15585/mmwr.mm7111a1
  • [9] Tobacco Product Use Among Adults - United States, 2019
    Cornelius, Monica E.
    Wang, Teresa W.
    Jamal, Ahmed
    Loretan, Caitlin G.
    Neff, Linda J.
    [J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2020, 69 (46): : 1736 - 1742
  • [10] D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO